A Phase 3 interventional study of Dermabond (2-Octylcyanoacrylate) and Swiftset (N-butyl-2-cyanoacrylate) in Dermatitis, Contact, sponsored by The University of Texas Health Science Center, Houston. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by The University of Texas Health Science Center, Houston · Phase 3, Interventional, and Treatment
This is a multi-center randomized controlled trial to evaluate two different methods of reinforcing surgical port site closure: 2-Octylcyanoacrylate and n-butyl-2-cyanoacrylate.
Study Design
This is a multi-center randomized controlled trial to evaluate two different methods of reinforcing surgical port site closure: 2-Octylcyanoacrylate and n-butyl-2-cyanoacrylate.
Methods
Inclusion Criteria All adult patients undergoing an elective laparoscopic or robotic abdominal surgery with the Minimally Invasive Surgeons of Texas (MIST) either at Texas Medical Center or Sugar Land will be eligible.
Exclusion criteria
Treatment Groups Eligible patients will be approached by research staff either in clinic or in pre-operative holding for trial enrollment. Each patient will serve as their own control. Enrolled patients will have both surgical glue types used, one on each half of their abdomen. The side for each glue will be randomly assigned by the day of the month. On odd days, 2-Octylcyanoacrylate will go on the patient's left abdomen. On even days, 2-Octylcyanoacrylate will go on the patient's right abdomen. If there is an odd number of incisions, the extra incision will be included on the patient's left.
All incisions will be closed with Monocryl. Closed incisions will be covered with skin glue.
Outcome The primary outcome of this trial will be the proportion of patients with contact dermatitis within 6 weeks post-operative. A trained surgical clinician blinded to the treatment arms will collect outcomes at all follow up clinic visits in the first 6 weeks post-operative. Any skin reaction will be documented with photographs.
Secondary outcome will include the diameter of erythema around any skin reaction, or any wound dehiscence or surgical site infection.
94 studies on the registry are indexed under Dermatitis, Contact; 14 are open to participants now.
This study's enrollment of 180 is above the median of 40 across 75 interventional studies indexed under Dermatitis, Contact.
Browse Dermatitis, Contact studies →The University of Texas Health Science Center, Houston is the lead sponsor of 880 studies on the registry; 209 are open to participants now.
Of its 170 completed or terminated interventional studies of FDA-regulated products, 140 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dermabond over incisions
Device: Dermabond (2-Octylcyanoacrylate)
Swiftset over incisions
Device: Swiftset (N-butyl-2-cyanoacrylate)
Liquiband over incisions
Device: Liquiband (2-Octylcyanoacrylate)
Incisions on left will have one glue and on right will have the other glue
Incisions on left will have one glue and on right will have the other glue
Incisions on left will have one glue and on right will have the other glue
Number of Participants Who Develop Contact Dermatitis
Contact Dermatitis is defined as erythema or rash around incisions
Time frame: 6 weeks
Mean Diameter of Erythema
mean diameter of erythema around incisions for those with contact dermatitis
Time frame: 6 weeks
Number of Participants With Wound Dehiscence
Time frame: 6 weeks
Number of Participants With Surgical Site Infection
Time frame: 6 weeks
| Milestone | Dermabond (2-Octylcyanoacrylate) | Swiftset (N-butyl-2-cyanoacrylate) | Liquiband (2-Octylcyanoacrylate) |
|---|---|---|---|
| Started | 180 | 0 | 180 |
| Completed | 179 | 0 | 179 |
| Not completed | 1 | 0 | 1 |
Contact Dermatitis is defined as erythema or rash around incisions
| Participants | Dermabond (2-Octylcyanoacrylate) | Liquiband (2-Octylcyanoacrylate) |
|---|---|---|
| Number of Participants Who Develop Contact Dermatitis | 21 | 18 |
mean diameter of erythema around incisions for those with contact dermatitis
No measurements were reported for this outcome.
| Participants | Dermabond (2-Octylcyanoacrylate) | Liquiband (2-Octylcyanoacrylate) |
|---|---|---|
| Number of Participants With Wound Dehiscence | 0 | 0 |
| Participants | Dermabond (2-Octylcyanoacrylate) | Liquiband (2-Octylcyanoacrylate) |
|---|---|---|
| Number of Participants With Surgical Site Infection | 0 | 0 |
Collected over Up to 6 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dermabond (2-Octylcyanoacrylate) | 0/180 (0%) | 0/180 (0%) | 21/180 (11.7%) |
| Liquiband (2-Octylcyanoacrylate) | 0/180 (0%) | 0/180 (0%) | 18/180 (10%) |
| Swiftset (N-butyl-2-cyanoacrylate) | — | — | — |
| Event | Dermabond (2-Octylcyanoacrylate) | Liquiband (2-Octylcyanoacrylate) | Swiftset (N-butyl-2-cyanoacrylate) |
|---|---|---|---|
| Contact DermatitisSkin and subcutaneous tissue disorders | 21/180 | 18/180 | — |
Participants served as their own control in this split-person design, with each receiving both surgical glue types applied to opposite sides of the abdomen. Baseline characteristics are reported at the participant level using a single group ("All Participants") to avoid double counting.
| Age, Continuous(years) | All Participants |
|---|---|
| Median | 47 (37 to 55) |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 131 |
| Male | 49 |
| Race and Ethnicity Not Collected(Participants) | All Participants |
|---|
| Region of Enrollment(participants) | All Participants |
|---|---|
| United States | 180 |
| Type of Surgery(Participants) | All Participants |
|---|---|
| Cholecystectomy | 3 |
| Duodenal Switch | 12 |
| Gastric Bypass | 56 |
| Hiatal Hernia Repair | 9 |
| Inguinal Hernia Repair | 17 |
| Revisional Bariatric | 35 |
| Sleeve Gastrectomy | 40 |
| Small Bowl Resection | 2 |
| Ventral Hernia Repair | 6 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Health Science Center, Houston